Therapeutic Response

ABL1 p.T315I and not BCR::ABL1 status confers therapeutic sensitivity to Ponatinib in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description
Iclusig (ponatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.